Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The discovery and characterization of 7k (BMS-582949), a highly selective p38α MAP kinase inhibitor that is currently in phase II clinical trials for the treatment of rheumatoid arthritis, is described. A key to the discovery was the rational substitution of N-cyclopropyl for N-methoxy in 1a, a previously reported clinical candidate p38α inhibitor. Unlike alkyl and other cycloalkyls, the sp(2) character of the cyclopropyl group can confer improved H-bonding characteristics to the directly substituted amide NH. Inhibitor 7k is slightly less active than 1a in the p38α enzymatic assay but displays a superior pharmacokinetic profile and, as such, was more effective in both the acute murine model of inflammation and pseudoestablished rat AA model. The binding mode of 7k with p38α was confirmed by X-ray crystallographic analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The as-yet unfulfilled promise of p38 MAPK inhibitors
Sweeney, S. E. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.171 · Cited by 38
Cited by
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Yang, Y., Kim, S. C., Yu, T., Yi, Y.-S., Rhee, M. H., Sung, G.-H., Yoo, B. C., & Cho, J. Y. (2014) · Mediators of Inflammation · doi:10.1155/2014/352371 · Cited by 406
Mitogen-Activated Protein Kinases as Therapeutic Targets for Rheumatoid Arthritis
Paunovic, V., & Harnett, M. M. (2013) · Drugs · doi:10.1007/s40265-013-0014-6 · Cited by 61
“BMS-582949, F) has generated a dual action p38 inhibitor that circumvents the resistance mechanisms that result in tachyphylaxis in clinical trials [143, 150, 151].”
BackgroundOld and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development
Sardar, S., & Andersson, Å. (2016) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1125917 · Cited by 50
Metadata
- Authors
- Liu, C., Lin, J., Wrobleski, S. T., Lin, S., Hynes, J., Wu, H., Dyckman, A. J., Li, T., Wityak, J., Gillooly, K. M., Pitt, S., Shen, D. R., Zhang, R. F., McIntyre, K. W., Salter-Cid, L., Shuster, D. J., Zhang, H., Marathe, P. H., Doweyko, A. M., Sack, J. S., Kiefer, S. E., Kish, K. F., Newitt, J. A., McKinnon, M., Dodd, J. H., Barrish, J. C., Schieven, G. L., & Leftheris, K.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-08-30
- Volume
- 53
- Issue
- 18
- Pages
- 6629-6639
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2090277801
- Cited by
- 56
- References
- 1
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases. https://app.cochat.ai/papers/10.1021/jm100540x
- The paper
- Liu, C., Lin, J., Wrobleski, S. T., Lin, S., Hynes, J., Wu, H., Dyckman, A. J., Li, T., Wityak, J., Gillooly, K. M., Pitt, S., Shen, D. R., Zhang, R. F., McIntyre, K. W., Salter-Cid, L., Shuster, D. J., Zhang, H., Marathe, P. H., Doweyko, A. M., . . . Leftheris, K. (2010). Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm100540x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.